3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline
February 2025
in “
Advanced Healthcare Materials
”
TLDR Perhexiline can effectively target ovarian cancer cells left after treatment.
The study introduces a microfluidics platform for creating 3D microtumors that effectively mimic ovarian cancer minimal residual disease (MRD), offering a more accurate model than traditional 2D cultures. These microtumors replicate key features such as hypoxia and lipid metabolism, and they exhibit higher resistance to chemotherapy, reflecting the drug-resistant nature of MRD. The study demonstrates that the fatty acid oxidation inhibitor Perhexiline significantly reduces MRD cell viability in these 3D models, highlighting its potential as a therapeutic agent. This platform provides a promising tool for drug testing and understanding resistance mechanisms, advancing personalized treatment strategies for ovarian cancer.